Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GIP Receptor Antagonist, SKL-14959 Indicated Alteration of the Lipids Metabolism to Catabolism by the Inhibition of Plasma LPL Activity, Resulting in the Suppression of Weight Gain on Diets-Induced Obesity Mice
Takashi Nakamura, Hitomi Tanimoto, Masayuki Okamoto, et al.
Diabetes Metabolic Syndrome and Obesity (2021) Vol. Volume 14, pp. 1095-1105
Open Access | Times Cited: 9

Showing 9 citing articles:

The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. S3, pp. 5-29
Closed Access | Times Cited: 221
Glucose-dependent insulinotropic polypeptide (GIP)
Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, et al.
Molecular Metabolism (2025) Vol. 95, pp. 102118-102118
Open Access | Times Cited: 3
Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
Ruili Yin, Yongsong Xu, Xin Wang, et al.
Molecules (2022) Vol. 27, Iss. 10, pp. 3055-3055
Open Access | Times Cited: 52
360-Degree Perspectives on Obesity
Magdalena Cuciureanu, Cătălin-Cezar Caratașu, Levon Gabrielian, et al.
Medicina (2023) Vol. 59, Iss. 6, pp. 1119-1119
Open Access | Times Cited: 21
Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
Zijun Ma, Kaiqin Jin, Mengmeng Yue, et al.
Journal of Diabetes Research (2023) Vol. 2023, pp. 1-8
Open Access | Times Cited: 11
GIP-derived GIP receptor antagonists – a review of their role in GIP receptor pharmacology
Mette M. Rosenkilde, Peter Lindquist, Hüsün Sheyma Kizilkaya, et al.
Peptides (2024) Vol. 177, pp. 171212-171212
Open Access | Times Cited: 2
Rate-Limiting Enzymes in Cardiometabolic Health and Aging in Humans
Laurence D. Parnell, Kira S. McCaffrey, Athena W. Brooks, et al.
Lifestyle Genomics (2023), pp. 124-138
Open Access | Times Cited: 5
Recent clinical and pharmacological advancements of incretin-based therapy and the effects of incretin on physiology
Bhaskar Pal, Moitreyee Chattopadhyay
Journal of Diabetology (2024) Vol. 15, Iss. 1, pp. 24-37
Open Access | Times Cited: 1
Therapeutic potentials of glucose-dependent insulinotropic polypeptide (GIP) in T2DM: Past, present, and future
Soumik Das, Harini Ravi, Achsha Babu, et al.
Advances in protein chemistry and structural biology (2024)
Closed Access
Page 1

Scroll to top